VCM
NAGE

Versant Capital Management’s Niagen Bioscience NAGE Stock Holding History

Versant Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-69
Closed -$304 – 2869
2026
Q1 		$304 Sell
69
-1,055
-94% -$5.7K ﹤0.01% 2746
2025
Q4 		$7.15K Sell
1,124
-968
-46% -$6.74K ﹤0.01% 2119
2025
Q3 		$19.5K Hold
2,092
– – ﹤0.01% 1592
2025
Q2 		$30.1K Buy
2,092
+968
+86% +$9.56K ﹤0.01% 1277
2025
Q1 		$7.76K Buy
+1,124
New +$7.06K ﹤0.01% 1845

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Versant Capital Management's NAGE Position: Q2 2026 in Review

Versant Capital Management sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 69 shares — an estimated $304 sold.

Versant Capital Management first reported a position in NAGE in Q1 2025 and held it in 5 quarters. The position peaked at $30.1K in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Versant Capital Management reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 69 Niagen Bioscience shares in Q2 2026, an estimated $304.
  • Versant Capital Management first reported a position in Niagen Bioscience in Q1 2025 and held it in 5 quarters.
  • Versant Capital Management's Niagen Bioscience position peaked at $30.1K in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.